studies

breast cancer (BC), anti-PD-(L)1 vs. chemotherapy, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsIMpassion-031 (all population), 2020 0.69 [0.25; 1.89] IMpassion-130 (all population), 2018 0.86 [0.72; 1.02] IMpassion-130 (PDL1>1%), 2018 0.71 [0.54; 0.94] KEYNOTE-119 (all population), 2019 0.97 [0.82; 1.15] KEYNOTE-119 (PDL1 CPS>1), 2019 0.86 [0.69; 1.07] KEYNOTE-119 (PDL1 CPS>10), 2019 0.78 [0.57; 1.06] KEYNOTE-355 (all population), 2020 0.89 [0.76; 1.05] KEYNOTE-355 (CPS>1), 2020 0.86 [0.72; 1.03] KEYNOTE-355 (CPS>10), 2020 0.73 [0.56; 0.96] 0.86[0.80; 0.92]IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018, IMpassion-130 (PDL1>1%), 2018, KEYNOTE-119 (all population), 2019, KEYNOTE-119 (PDL1 CPS>1), 2019, KEYNOTE-119 (PDL1 CPS>10), 2019, KEYNOTE-355 (all population), 2020, KEYNOTE-355 (CPS>1), 2020, KEYNOTE-355 (CPS>10), 202090%4,631lowserious PFS (extension)detailed resultsIMpassion-130 (all population), 2018 0.80 [0.69; 0.92] IMpassion-130 (PDL1>1%), 2018 0.63 [0.50; 0.80] 0.72[0.57; 0.91]IMpassion-130 (all population), 2018, IMpassion-130 (PDL1>1%), 2018265%1,271lownot evaluable progression or deaths (PFS)detailed resultsIMpassion-130 (all population), 2018 0.80 [0.69; 0.92] IMpassion-130 (PDL1>1%), 2018 0.62 [0.49; 0.78] KEYNOTE-119 (all population), 2019 1.60 [1.33; 1.92] KEYNOTE-119 (PDL1 CPS>1), 2019 1.35 [1.08; 1.68] KEYNOTE-119 (PDL1 CPS>10), 2019 1.14 [0.82; 1.59] KEYNOTE-355 (all population), 2020 0.82 [0.69; 0.97] KEYNOTE-355 (CPS>1), 2020 0.75 [0.62; 0.91] KEYNOTE-355 (CPS>10), 2020 0.66 [0.50; 0.88] 0.92[0.72; 1.16]IMpassion-130 (all population), 2018, IMpassion-130 (PDL1>1%), 2018, KEYNOTE-119 (all population), 2019, KEYNOTE-119 (PDL1 CPS>1), 2019, KEYNOTE-119 (PDL1 CPS>10), 2019, KEYNOTE-355 (all population), 2020, KEYNOTE-355 (CPS>1), 2020, KEYNOTE-355 (CPS>10), 2020891%4,298lownot evaluable DCRdetailed resultsKEYNOTE-119 (all population), 2019 0.60 [0.39; 0.94] 0.60[0.39; 0.94]KEYNOTE-119 (all population), 201910%622NAnot evaluable DORdetailed resultsIMpassion-130 (all population), 2018 0.78 [0.63; 0.97] IMpassion-130 (PDL1>1%), 2018 0.60 [0.42; 0.85] 0.71[0.55; 0.91]IMpassion-130 (all population), 2018, IMpassion-130 (PDL1>1%), 2018236%369lownot evaluable events or deaths (EFS)detailed resultsIMpassion-031 (all population), 2020 0.76 [0.40; 1.44] 0.76[0.40; 1.44]IMpassion-031 (all population), 202010%333NAnot evaluable objective responses (ORR)detailed resultsIMpassion-130 (all population), 2018 1.52 [1.17; 1.98] IMpassion-130 (PDL1>1%), 2018 1.96 [1.29; 2.98] KEYNOTE-119 (all population), 2019 0.89 [0.53; 1.50] KEYNOTE-119 (PDL1 CPS>1), 2019 1.35 [0.72; 2.54] KEYNOTE-119 (PDL1 CPS>10), 2019 2.13 [0.90; 5.04] KEYNOTE-355 (all population), 2020 0.24 [0.17; 0.33] KEYNOTE-355 (CPS>1), 2020 1.28 [0.92; 1.80] KEYNOTE-355 (CPS>10), 2020 1.62 [1.01; 2.60] 1.16[0.65; 2.07]IMpassion-130 (all population), 2018, IMpassion-130 (PDL1>1%), 2018, KEYNOTE-119 (all population), 2019, KEYNOTE-119 (PDL1 CPS>1), 2019, KEYNOTE-119 (PDL1 CPS>10), 2019, KEYNOTE-355 (all population), 2020, KEYNOTE-355 (CPS>1), 2020, KEYNOTE-355 (CPS>10), 2020894%4,298lownot evaluable pCR detailed resultsIMpassion-031 (all population), 2020 1.95 [1.26; 3.01] IMpassion-031 (PDL1>1%), 2020 2.23 [1.16; 4.30] 2.03[1.41; 2.92]IMpassion-031 (all population), 2020, IMpassion-031 (PDL1>1%), 202020%487lownot evaluable AE (any grade)detailed resultsIMpassion-031 (all population), 2020 0.49 [0.02; 14.69] IMpassion-130 (all population), 2018 3.15 [0.85; 11.73] KEYNOTE-355 (all population), 2020 1.25 [0.41; 3.87] 1.71[0.75; 3.93]IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018, KEYNOTE-355 (all population), 202030%2,064lownot evaluable AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.10 [0.71; 1.72] IMpassion-130 (all population), 2018 1.31 [1.00; 1.70] KEYNOTE-355 (all population), 2020 1.26 [0.91; 1.76] 1.25[1.04; 1.51]IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018, KEYNOTE-355 (all population), 202030%2,064lownot evaluable AE leading to death (grade 5)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.06; 16.42] IMpassion-130 (all population), 2018 1.94 [0.48; 7.81] 1.71[0.49; 5.92]IMpassion-031 (all population), 2020, IMpassion-130 (all population), 201820%1,221lownot evaluable AE leading to treatment discontinuation (any grade)detailed resultsIMpassion-031 (all population), 2020 1.18 [0.70; 2.01] IMpassion-130 (all population), 2018 2.24 [1.46; 3.43] 1.66[0.89; 3.11]IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018271%1,221lownot evaluable SAE (any grade)detailed resultsIMpassion-031 (all population), 2020 2.00 [1.20; 3.36] IMpassion-130 (all population), 2018 1.33 [0.96; 1.84] KEYNOTE-119 (all population), 2019 0.99 [0.66; 1.48] 1.34[0.94; 1.90]IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018, KEYNOTE-119 (all population), 2019355%1,822lownot evaluable STRAE (any grade)detailed resultsIMpassion-031 (all population), 2020 1.58 [0.91; 2.75] IMpassion-130 (all population), 2018 1.82 [1.16; 2.87] 1.72[1.21; 2.45]IMpassion-031 (all population), 2020, IMpassion-130 (all population), 201820%1,221lownot evaluable TRAE (any grade)detailed resultsIMpassion-031 (all population), 2020 0.98 [0.14; 7.05] IMpassion-130 (all population), 2018 1.80 [0.96; 3.39] KEYNOTE-355 (all population), 2020 1.35 [0.68; 2.70] 1.54[0.98; 2.42]IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018, KEYNOTE-355 (all population), 202030%2,064lownot evaluable TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.15 [0.74; 1.77] IMpassion-130 (all population), 2018 1.52 [1.15; 2.01] KEYNOTE-119 (all population), 2019 0.29 [0.19; 0.43] KEYNOTE-355 (all population), 2020 1.06 [0.78; 1.44] 0.86[0.44; 1.69]IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018, KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020494%2,665lownot evaluable TRAE leading to death (grade 5)detailed resultsIMpassion-130 (all population), 2018 1.93 [0.17; 21.40] KEYNOTE-119 (all population), 2019 0.94 [0.37; 2.41] KEYNOTE-355 (all population), 2020 2.00 [0.09; 44.58] 1.09[0.47; 2.52]IMpassion-130 (all population), 2018, KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 202030%2,334moderatenot evaluable TRAE leading to discontinuation (any grade)detailed resultsKEYNOTE-119 (all population), 2019 1.05 [0.42; 2.63] 1.05[0.42; 2.63]KEYNOTE-119 (all population), 201910%601NAnot evaluable Abdominal pain TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.94 [0.06; 15.18] 0.94[0.06; 15.18]KEYNOTE-119 (all population), 201910%601NAnot evaluable Acute kidney injury TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11] 0.47[0.02; 14.11]KEYNOTE-119 (all population), 201910%601NAnot evaluable Adrenal insufficiency TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] KEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64] 1.45[0.11; 18.96]IMpassion-031 (all population), 2020, KEYNOTE-119 (all population), 201920%932moderatenot evaluable Alopecia TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.94 [0.02; 47.78] KEYNOTE-355 (all population), 2020 0.83 [0.20; 3.51] 0.84[0.22; 3.26]KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 202020%1,444lownot evaluable Anaemia TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.28 [0.08; 1.01] KEYNOTE-355 (all population), 2020 1.15 [0.77; 1.71] 0.65[0.17; 2.54]KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020276%1,444lownot evaluable Asthenia TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 1.26 [0.28; 5.69] 1.26[0.28; 5.69]KEYNOTE-119 (all population), 201910%601NAnot evaluable Colitis TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 2.04 [0.07; 61.32] KEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11] KEYNOTE-355 (all population), 2020 2.00 [0.09; 44.58] 1.28[0.19; 8.58]IMpassion-031 (all population), 2020, KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 202030%1,775lownot evaluable Constipation TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11] 0.47[0.02; 14.11]KEYNOTE-119 (all population), 201910%601NAnot evaluable Cough TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64] 1.89[0.06; 56.64]KEYNOTE-119 (all population), 201910%601NAnot evaluable Decreased appetite TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11] 0.47[0.02; 14.11]KEYNOTE-119 (all population), 201910%601NAnot evaluable Diabetes TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] KEYNOTE-119 (all population), 2019 0.94 [0.06; 15.18] 0.97[0.10; 9.35]IMpassion-031 (all population), 2020, KEYNOTE-119 (all population), 201920%932moderatenot evaluable Diarrhoea TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.23 [0.05; 1.10] 0.23[0.05; 1.10]KEYNOTE-119 (all population), 201910%601NAnot evaluable Dyspnoea TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64] 1.89[0.06; 56.64]KEYNOTE-119 (all population), 201910%601NAnot evaluable Fatigue TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.94 [0.19; 4.72] KEYNOTE-355 (all population), 2020 1.15 [0.47; 2.82] 1.10[0.50; 2.40]KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 202020%1,444lownot evaluable Febrile neutropenia TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.05 [0.00; 0.79] 0.05[0.00; 0.79]KEYNOTE-119 (all population), 201910%601NAnot evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 0.51 [0.02; 15.24] 0.51[0.02; 15.24]IMpassion-031 (all population), 202010%331NAnot evaluable Headache TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64] 1.89[0.06; 56.64]KEYNOTE-119 (all population), 201910%601NAnot evaluable Hepatitis TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] 1.02[0.02; 51.63]IMpassion-031 (all population), 202010%331NAnot evaluable Hyperthyroidism TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] KEYNOTE-119 (all population), 2019 0.94 [0.02; 47.78] KEYNOTE-355 (all population), 2020 1.00 [0.03; 29.90] 0.99[0.12; 8.48]IMpassion-031 (all population), 2020, KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 202030%1,775lownot evaluable Hypothyroidism TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] KEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64] KEYNOTE-355 (all population), 2020 2.00 [0.09; 44.58] 1.65[0.23; 11.97]IMpassion-031 (all population), 2020, KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 202030%1,775lownot evaluable Increase AST TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 1.91 [0.57; 6.42] 1.91[0.57; 6.42]KEYNOTE-119 (all population), 201910%601NAnot evaluable Increased ALT TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 1.90 [0.17; 21.02] KEYNOTE-355 (all population), 2020 1.29 [0.67; 2.48] 1.32[0.70; 2.49]KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 202020%1,444lownot evaluable Infusion-related reactions TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.06; 16.42] 1.02[0.06; 16.42]IMpassion-031 (all population), 202010%331NAnot evaluable Leucopenia TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.09 [0.01; 1.71] KEYNOTE-355 (all population), 2020 0.83 [0.58; 1.19] 0.46[0.07; 3.09]KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020253%1,444lownot evaluable Maculopapular rash TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64] 1.89[0.06; 56.64]KEYNOTE-119 (all population), 201910%601NAnot evaluable Myalgia TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11] 0.47[0.02; 14.11]KEYNOTE-119 (all population), 201910%601NAnot evaluable Myositis TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 2.04 [0.07; 61.32] KEYNOTE-119 (all population), 2019 5.72 [0.29; 114.60] 3.65[0.38; 34.56]IMpassion-031 (all population), 2020, KEYNOTE-119 (all population), 201920%932moderatenot evaluable Nausea TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11] KEYNOTE-355 (all population), 2020 1.13 [0.34; 3.69] 1.03[0.33; 3.14]KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 202020%1,444lownot evaluable Nephritis TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.94 [0.02; 47.78] 0.94[0.02; 47.78]KEYNOTE-119 (all population), 201910%601NAnot evaluable Neutropenia TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.01 [0.00; 0.12] KEYNOTE-355 (all population), 2020 0.99 [0.73; 1.36] 0.11[0.00; 12.49]KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 2020291%1,444lownot evaluable Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.13 [0.02; 1.08] 0.13[0.02; 1.08]KEYNOTE-119 (all population), 201910%601NAnot evaluable Pancytopenia TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.24 [0.01; 5.23] 0.24[0.01; 5.23]KEYNOTE-119 (all population), 201910%601NAnot evaluable Peripheral sensory neuropathy TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.16 [0.01; 3.13] 0.16[0.01; 3.13]KEYNOTE-119 (all population), 201910%601NAnot evaluable Pneumonia TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.24 [0.01; 5.23] 0.24[0.01; 5.23]KEYNOTE-119 (all population), 201910%601NAnot evaluable Pneumonitis TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 2.04 [0.07; 61.32] KEYNOTE-119 (all population), 2019 5.72 [0.29; 114.60] KEYNOTE-355 (all population), 2020 6.05 [0.34; 108.78] 4.41[0.75; 26.04]IMpassion-031 (all population), 2020, KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 202030%1,775lownot evaluable Pruritus TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64] 1.89[0.06; 56.64]KEYNOTE-119 (all population), 201910%601NAnot evaluable Pyrexia TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.94 [0.06; 15.18] 0.94[0.06; 15.18]KEYNOTE-119 (all population), 201910%601NAnot evaluable Rash TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.32; 3.23] 1.02[0.32; 3.23]IMpassion-031 (all population), 202010%331NAnot evaluable Sepsis TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.94 [0.02; 47.78] 0.94[0.02; 47.78]KEYNOTE-119 (all population), 201910%601NAnot evaluable Severe skin reaction TRAE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] KEYNOTE-119 (all population), 2019 1.90 [0.17; 21.02] KEYNOTE-355 (all population), 2020 10.16 [0.59; 174.64] 3.01[0.57; 15.90]IMpassion-031 (all population), 2020, KEYNOTE-119 (all population), 2019, KEYNOTE-355 (all population), 202030%1,775lownot evaluable Stomatitis TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.47 [0.02; 14.11] 0.47[0.02; 14.11]KEYNOTE-119 (all population), 201910%601NAnot evaluable Thrombocytopenia TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.94 [0.06; 15.18] 0.94[0.06; 15.18]KEYNOTE-119 (all population), 201910%601NAnot evaluable Thyroiditis TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.94 [0.02; 47.78] 0.94[0.02; 47.78]KEYNOTE-119 (all population), 201910%601NAnot evaluable Urticaria TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 1.89 [0.06; 56.64] 1.89[0.06; 56.64]KEYNOTE-119 (all population), 201910%601NAnot evaluable Weight decreased TRAE (grade 3-4)detailed resultsKEYNOTE-119 (all population), 2019 0.47 [0.04; 5.22] 0.47[0.04; 5.22]KEYNOTE-119 (all population), 201910%601NAnot evaluable hepatitis (Autoimmune) AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 0.96 [0.06; 15.47] 0.96[0.06; 15.47]IMpassion-130 (all population), 201810%890NAnot evaluable Abdominal pain AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 0.51 [0.02; 15.24] IMpassion-130 (all population), 2018 1.93 [0.17; 21.40] 1.24[0.17; 8.82]IMpassion-031 (all population), 2020, IMpassion-130 (all population), 201820%1,221lownot evaluable Acute kidney injury AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 1.93 [0.06; 57.72] 1.93[0.06; 57.72]IMpassion-130 (all population), 201810%890NAnot evaluable Adrenal insufficiency AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 1.93 [0.06; 57.72] 1.93[0.06; 57.72]IMpassion-130 (all population), 201810%890NAnot evaluable Alopecia AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] IMpassion-130 (all population), 2018 1.93 [0.17; 21.40] 1.62[0.21; 12.61]IMpassion-031 (all population), 2020, IMpassion-130 (all population), 201820%1,221lownot evaluable Anaemia AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.21 [0.54; 2.69] IMpassion-130 (all population), 2018 1.04 [0.48; 2.24] 1.12[0.64; 1.94]IMpassion-031 (all population), 2020, IMpassion-130 (all population), 201820%1,221lownot evaluable Arthralgia AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] IMpassion-130 (all population), 2018 0.96 [0.06; 15.47] 0.98[0.10; 9.47]IMpassion-031 (all population), 2020, IMpassion-130 (all population), 201820%1,221lownot evaluable Asthenia AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.54 [0.25; 9.32] IMpassion-130 (all population), 2018 0.72 [0.16; 3.24] 0.98[0.31; 3.12]IMpassion-031 (all population), 2020, IMpassion-130 (all population), 201820%1,221lownot evaluable Back pain AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] IMpassion-130 (all population), 2018 2.92 [0.59; 14.54] 2.51[0.57; 11.10]IMpassion-031 (all population), 2020, IMpassion-130 (all population), 201820%1,221lownot evaluable Cardiomyopathy AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 1.93 [0.06; 57.72] 1.93[0.06; 57.72]IMpassion-130 (all population), 201810%890NAnot evaluable Chills AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 1.93 [0.06; 57.72] 1.93[0.06; 57.72]IMpassion-130 (all population), 201810%890NAnot evaluable Colitis AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 0.96 [0.06; 15.47] 0.96[0.06; 15.47]IMpassion-130 (all population), 201810%890NAnot evaluable Constipation AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 0.51 [0.02; 15.24] IMpassion-130 (all population), 2018 2.91 [0.30; 28.05] 1.70[0.26; 11.21]IMpassion-031 (all population), 2020, IMpassion-130 (all population), 201820%1,221lownot evaluable Cough AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] IMpassion-130 (all population), 2018 0.96 [0.02; 48.73] 0.99[0.06; 15.89]IMpassion-031 (all population), 2020, IMpassion-130 (all population), 201820%1,221lownot evaluable Decreased appetite AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] IMpassion-130 (all population), 2018 0.96 [0.19; 4.80] 0.97[0.22; 4.30]IMpassion-031 (all population), 2020, IMpassion-130 (all population), 201820%1,221lownot evaluable Diarrhoea AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 4.15 [0.46; 37.53] IMpassion-130 (all population), 2018 0.85 [0.33; 2.24] 1.36[0.33; 5.60]IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018240%1,221lownot evaluable Dizziness AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 0.96 [0.02; 48.73] 0.96[0.02; 48.73]IMpassion-130 (all population), 201810%890NAnot evaluable Dry skin AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 2.04 [0.07; 61.32] 2.04[0.07; 61.32]IMpassion-031 (all population), 202010%331NAnot evaluable Dysgeusia AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] IMpassion-130 (all population), 2018 0.96 [0.02; 48.73] 0.99[0.06; 15.89]IMpassion-031 (all population), 2020, IMpassion-130 (all population), 201820%1,221lownot evaluable Dyspepsia AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] 1.02[0.02; 51.63]IMpassion-031 (all population), 202010%331NAnot evaluable Dysphonia AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 1.93 [0.06; 57.72] 1.93[0.06; 57.72]IMpassion-130 (all population), 201810%890NAnot evaluable Dyspnoea AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.14; 7.32] IMpassion-130 (all population), 2018 0.96 [0.19; 4.80] 0.99[0.28; 3.42]IMpassion-031 (all population), 2020, IMpassion-130 (all population), 201820%1,221lownot evaluable Epistaxis AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] 1.02[0.02; 51.63]IMpassion-031 (all population), 202010%331NAnot evaluable Fatigue AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.23 [0.37; 4.11] IMpassion-130 (all population), 2018 1.10 [0.54; 2.22] 1.13[0.61; 2.08]IMpassion-031 (all population), 2020, IMpassion-130 (all population), 201820%1,221lownot evaluable Febrile neutropenia AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.25 [0.61; 2.57] 1.25[0.61; 2.57]IMpassion-031 (all population), 202010%331NAnot evaluable Headache AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 0.51 [0.02; 15.24] IMpassion-130 (all population), 2018 0.48 [0.09; 2.63] 0.49[0.11; 2.23]IMpassion-031 (all population), 2020, IMpassion-130 (all population), 201820%1,221lownot evaluable Hypertension AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 0.84 [0.35; 2.00] IMpassion-130 (all population), 2018 0.35 [0.11; 1.09] 0.59[0.25; 1.38]IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018231%1,221lownot evaluable Hyperthyroidism AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 1.93 [0.06; 57.72] 1.93[0.06; 57.72]IMpassion-130 (all population), 201810%890NAnot evaluable Hypothyroidism AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 0.96 [0.02; 48.73] 0.96[0.02; 48.73]IMpassion-130 (all population), 201810%890NAnot evaluable Increase AST AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 2.44 [0.62; 9.59] IMpassion-130 (all population), 2018 0.96 [0.38; 2.45] 1.33[0.56; 3.16]IMpassion-031 (all population), 2020, IMpassion-130 (all population), 2018217%1,221lownot evaluable Increased ALT AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 0.91 [0.36; 2.30] IMpassion-130 (all population), 2018 1.55 [0.50; 4.79] 1.13[0.55; 2.31]IMpassion-031 (all population), 2020, IMpassion-130 (all population), 201820%1,221lownot evaluable Infusion-related reaction AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.06; 16.42] 1.02[0.06; 16.42]IMpassion-031 (all population), 202010%331NAnot evaluable Lacrimation increased AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.02 [0.02; 51.63] 1.02[0.02; 51.63]IMpassion-031 (all population), 202010%331NAnot evaluable Leucopenia AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 1.86 [0.76; 4.55] IMpassion-130 (all population), 2018 1.55 [0.50; 4.79] 1.73[0.86; 3.49]IMpassion-031 (all population), 2020, IMpassion-130 (all population), 201820%1,221lownot evaluable Mucosal inflammation AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 2.04 [0.07; 61.32] IMpassion-130 (all population), 2018 1.94 [0.35; 10.63] 1.96[0.43; 8.98]IMpassion-031 (all population), 2020, IMpassion-130 (all population), 201820%1,221lownot evaluable Myalgia AE (grade 3-4)detailed resultsIMpassion-031 (all population), 2020 2.04 [0.07; 61.32] IMpassion-130 (all population), 2018 0.64 [0.11; 3.86] 0.83[0.17; 4.04]IMpassion-031 (all population), 2020, IMpassion-130 (all population), 201820%1,221lownot evaluable Myopathy AE (grade 3-4)detailed resultsIMpassion-130 (all population), 2018 1.93 [0.06; 57.72] 1.93[0.06; 57.72]IMpassion-130 (all population), 201810%890NAnot evaluable0.010.01.0relative treatment effectwww.metaEvidence.org2024-06-29 14:56 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 64,370,336,147,145,355,337,146,317,4,319,144,356,351,357,352,354,353,358,359,324,142,305,306,98,96,269,60,143,270,140,240,3 - treatments: 367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,854,374,1073,953,672,1080,862,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons